RedHill Biopharma (RDHL) Return on Sales: 2012-2023
Historic Return on Sales for RedHill Biopharma (RDHL) over the last 10 years, with Jun 2023 value amounting to -1.12%.
- RedHill Biopharma's Return on Sales rose 106.00% to -1.12% in Q2 2023 from the same period last year, while for Jun 2023 it was -1.12%, marking a year-over-year increase of 106.00%. This contributed to the annual value of -1.03% for FY2024, which is 469.00% down from last year.
- Per RedHill Biopharma's latest filing, its Return on Sales stood at -1.12% for Q2 2023, which was up 59.33% from -2.75% recorded in Q1 2023.
- In the past 5 years, RedHill Biopharma's Return on Sales registered a high of 9.27% during Q1 2020, and its lowest value of -2.80% during Q3 2022.
- In the last 3 years, RedHill Biopharma's Return on Sales had a median value of -1.20% in 2022 and averaged -1.10%.
- Per our database at Business Quant, RedHill Biopharma's Return on Sales surged by 426bps in 2020 and then slumped by 858bps in 2021.
- Quarterly analysis of 5 years shows RedHill Biopharma's Return on Sales stood at 7.01% in 2019, then plummeted by 614bps to 0.87% in 2020, then plummeted by 201bps to -1.14% in 2021, then tumbled by 85bps to -1.99% in 2022, then skyrocketed by 106bps to -1.12% in 2023.
- Its Return on Sales stands at -1.12% for Q2 2023, versus -2.75% for Q1 2023 and -1.99% for Q4 2022.